NCT06142461View on ClinicalTrials.gov

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

April 30, 2025

Conditions
Vaccine Reaction
Interventions
DRUG

Gardasil

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume

DRUG

Gardasil

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume

DRUG

Gardasil

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume

DEVICE

PharmaJet Stratis® Needle-Free Injection System

0.5mL dose injection

DEVICE

PharmaJet Tropis® Needle-Free Injection System

0.1mL dose injection

Trial Locations (1)

Unknown

Universitas Padjadjaran, Bandung

Sponsors

Lead Sponsor

PharmaJet, Inc.
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

PharmaJet, Inc.

INDUSTRY

NCT06142461 - Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System | Biotech Hunter | Biotech Hunter